EE05497B1 - Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha - Google Patents

Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Info

Publication number
EE05497B1
EE05497B1 EEP200100472A EEP200100472A EE05497B1 EE 05497 B1 EE05497 B1 EE 05497B1 EE P200100472 A EEP200100472 A EE P200100472A EE P200100472 A EEP200100472 A EE P200100472A EE 05497 B1 EE05497 B1 EE 05497B1
Authority
EE
Estonia
Prior art keywords
polypeptide
cram
polynucleotide
antibody
soluble
Prior art date
Application number
EEP200100472A
Other languages
English (en)
Estonian (et)
Inventor
Albert Imhof Beat
Aurrand-Lions Michel
Original Assignee
Rmf Dictagene S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene S.A. filed Critical Rmf Dictagene S.A.
Publication of EE200100472A publication Critical patent/EE200100472A/xx
Publication of EE05497B1 publication Critical patent/EE05497B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
EEP200100472A 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha EE05497B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (2)

Publication Number Publication Date
EE200100472A EE200100472A (et) 2002-12-16
EE05497B1 true EE05497B1 (et) 2011-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100472A EE05497B1 (et) 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Country Status (22)

Country Link
US (3) US7393651B2 (is)
EP (2) EP2292761A1 (is)
JP (2) JP4836329B2 (is)
CN (2) CN100469878C (is)
AT (1) ATE500328T1 (is)
AU (1) AU782139B2 (is)
BR (1) BR0008915A (is)
CA (1) CA2362896C (is)
CZ (1) CZ303128B6 (is)
DE (1) DE60045681D1 (is)
EE (1) EE05497B1 (is)
ES (1) ES2361905T3 (is)
HU (1) HU229376B1 (is)
IL (1) IL145310A0 (is)
IS (1) IS2819B (is)
MX (1) MXPA01009110A (is)
NO (1) NO333085B1 (is)
NZ (1) NZ514091A (is)
PL (1) PL207994B1 (is)
RU (1) RU2244748C2 (is)
WO (1) WO2000053749A2 (is)
ZA (1) ZA200107283B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
MXPA01009110A (es) * 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
AU2007301599B2 (en) 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
PT2190991T (pt) * 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
EP0973892A2 (en) * 1997-03-14 2000-01-26 Human Genome Sciences, Inc. 28 human secreted proteins
EP0970111A2 (en) * 1997-03-21 2000-01-12 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
PT1000149E (pt) 1997-08-01 2007-08-03 Serono Genetics Inst Sa 5' ests para proteínas segregadas identificadas a partir de tecidos do cérebro.
US20030092002A1 (en) 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
IL142794A0 (en) * 1998-12-16 2002-03-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2600800A (en) * 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
MXPA01009110A (es) * 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
IS6072A (is) 2001-09-10
ZA200107283B (en) 2002-12-24
IL145310A0 (en) 2003-01-12
NO20014417D0 (no) 2001-09-11
JP4836329B2 (ja) 2011-12-14
EP2292761A1 (en) 2011-03-09
US20050266426A1 (en) 2005-12-01
US7393651B2 (en) 2008-07-01
EP1163337A2 (en) 2001-12-19
ES2361905T3 (es) 2011-06-24
NO20014417L (no) 2001-11-12
CZ303128B6 (cs) 2012-04-18
JP2002537837A (ja) 2002-11-12
NZ514091A (en) 2004-01-30
IS2819B (is) 2012-12-15
US8143056B2 (en) 2012-03-27
US20080274970A1 (en) 2008-11-06
HUP0200606A3 (en) 2004-11-29
BR0008915A (pt) 2002-04-09
CN100469878C (zh) 2009-03-18
JP2010233572A (ja) 2010-10-21
WO2000053749A3 (en) 2000-12-14
EP1163337B1 (en) 2011-03-02
PL350417A1 (en) 2002-12-16
HK1044169A1 (en) 2002-10-11
CN1355843A (zh) 2002-06-26
CZ20013267A3 (cs) 2002-02-13
DE60045681D1 (de) 2011-04-14
US7670826B2 (en) 2010-03-02
CN1637019A (zh) 2005-07-13
AU4105100A (en) 2000-09-28
HU229376B1 (en) 2013-11-28
NO333085B1 (no) 2013-02-25
PL207994B1 (pl) 2011-02-28
EE200100472A (et) 2002-12-16
RU2244748C2 (ru) 2005-01-20
MXPA01009110A (es) 2002-08-20
CA2362896A1 (en) 2000-09-14
CA2362896C (en) 2012-07-31
US20100267649A1 (en) 2010-10-21
ATE500328T1 (de) 2011-03-15
HUP0200606A2 (en) 2002-06-29
AU782139B2 (en) 2005-07-07
WO2000053749A2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
ATE431359T1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
ATE132197T1 (de) Monoklonale antikörper
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
ATE115409T1 (de) Glykoprotein-hormonrezeptor-moleküle.
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
ATE301194T1 (de) Beta-defensine
ATE271125T1 (de) Neuartige tyrosinkinase
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
BR0007816A (pt) Fator de estimulação óssea
EP0832109A4 (en) FACTOR-2, HOMOLOGY OF THE FIBROBLASTS GROWTH FACTOR AND METHOD FOR ITS APPLICATION
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20180313